Carey K. Anders, MD, Duke Cancer Institute

Carey K. Anders, MD, discusses lessons learned from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Carey K. Anders, MD, discusses leveraging antibody-drug conjugates in the treatment of patients with metastatic triple-negative breast cancer.

Collectively, there are more options than ever in the space of HER2-positive breast cancer brain metastases, a significant advance for our hundreds and thousands of patients facing this challenging disease.